Karen Wagner

Dr. Karen Wagner is Managing Partner at Ysios Capital, a leading life sciences venture capital investor, where she focuses on therapeutic investments and coordinates the identification and evaluation of investment opportunities. Karen holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany, and has acquired some business skills at McKinsey. She joined Ysios in 2008, after over 10 years of experience in business development in various biotech and pharma companies, including GLYCART in Zurich and F.Hoffmann-La Roche in Basel. She serves on the board of Sparingvision, Vivet Therapeutics, AELIX Therapeutics and Minoryx Therapeutics and is an observer at the board of Xeltis. Formerly, she was board member at Cardoz, Galecto and Kala Pharmaceuticals.